Timothy Craig, DO
Professor, Medicine
Professor, Pediatrics
GHSP Site Leader: Vietnam, Global Health Scholars Pathway
Biography
Dr. Craig’s present research focus is rare diseases that include hereditary angioedema and alpha-1 anti tryptase deficiency (AATD), and immunology research with Vin University in Hanoi Vietnam.
Prior to this his team was involved in vaccine work with the NIAID, and asthma research with the NHLBI and sleep medicine. Over the years his laboratory, Allergy Immunology Respiratory (AIR Laboratory) has completed way over 100 clinical trials in asthma, rhinitis, sleep, vaccine work and allergic skin diseases. Dr. Craig has published over 700 abstracts, delivered over 500 invited lectures, and published over 425 manuscripts in peer reviewed journals. His early work on treatment of rhinitis and effects on sleep and therapeutic interventions are still frequently referenced.
The impact of his work on allergic skin disorders is illustrated by his senior author position for the international hereditary angioedema (HAE) guidelines published by the World Allergy Organization, the Global HAE guideline published in Allergy and the Pediatric HAE guidelines published in Allergy. In addition, he is an author on the Canadian, American and Latin American Guidelines for HAE and the International and American guidelines for urticaria and helped establish a center for atopic dermatitis in Vietnam. His group was one of the laboratories to work with Intellia for CRISPr therapy in HAE and was recently published in the NEJM.
ACARE and ACRN, were both large asthma clinical research networks of the NHLBI. Penn State University was the statistical center led by Vern Chinchilli and Dr Craig was the clinical advisor. Multiple publications, mainly published in the NEJM, helped develop modern asthma therapy and made substantial contributions to asthma guidelines.
Dr Craig's laboratory was one of the sites selected by NIAID to study hypersensitivity to the COVID Vaccine. Outcomes from these studies will be vital for vaccines strategies in future epidemics.
Finally, Dr Craig is part of a large immunology consortium at VinMec International Hospital and VinUniversity, both in the Hanoi Vietnam. The consortium treated their first patient with lupus with CAT T cells successfully and is developing strategies for CRISPr technology. The AIR laboratory, with Ms Richwine RN MA and Ms Grim RN MS, continues to be productive and is transforming how we will treat AATD and HAE in the future.